Table 1 ∣.
Limitations of CRISPR-Cas editing systems
| Application | Genomic editing technique | Advantages | Disadvantages |
|---|---|---|---|
| Identifying and investigating autoimmune-associated loci and genes | CRISPR–Cas-mediated genome wide screening30-34 | All annotated genes can be targeted | Limited to cell lines |
| Can discover cell type-specific effects | Requires a functional outcome (for example, proliferation) | ||
| CRISPR–Cas-mediated knockout of individual genes37,38 | Function can be assessed | Low throughput | |
| Amenable to primary immune cells | |||
| CRISPR–Cas-mediated activation (CRISPRa) or interference (CRISPRi) of gene expression61,64 | Easily multiplexable | Currently limited to cell lines | |
| Identifying autoimmune regulatory regions | CRISPR–Cas-mediated activation (CRISPRa) or interference (CRISPRi) of regulatory region60,62,63,65 | Can test any region of the genome | Effects might be context-dependent and require multiple cell lines for verification |
| CRISPR–Cas-mediated deletion or mutagenesis of regulatory regions55 | |||
| Identifying causal variants | CRISPR–Cas-mediated mutagenesis of causal variants58 | Amenable to primary immune cells | Induced deletions, insertions and substitutions are random and do not recapitulate variant changes |
| Some variants cannot be directly targeted | |||
| CRISPR–Cas-mediated homology directed repair80,83 | Can directly change reference allele to an alternative allele | Bystander mutations | |
| CRISPR–Cas-mediated base editing85-90 | Not all mutations are possible | ||
| CRISPR–Cas-mediated prime editing91 | Low efficiency | ||
| Linking variants to causal immune cell types | CRISPR–Cas-mediated editing paired with single-cell technologies101-105 | Can be used to directly identify cell populations of interest in rheumatic disorders | Expensive and prone to drop-out in gene expression |
| Can assess the function of a particular variant in a broad range of cell populations simultaneously |